01Purpose and principlesWhat the assessment is for and the core concepts behind it.
Testing begins after examination. In persistent small-joint synovitis, RF and anti-CCP alter the probability and prognosis of rheumatoid arthritis, but the referral decision is clinical. RF sensitivity is incomplete and specificity falls in low-prevalence populations. Anti-CCP is more disease-specific, particularly at higher concentrations, yet not every positive patient has current rheumatoid arthritis and not every affected patient is positive.
ANA detects antibodies binding nuclear antigens using assay-dependent methods. Positivity becomes more common at low titres in healthy people, with increasing age, during infection and with some medicines. Pre-test probability is therefore central. Appropriate clues include photosensitive or other characteristic rash, inflammatory arthritis, Raynaud phenomenon, ulcers, alopecia, sicca, serositis, cytopenia, proteinuria, haematuria or otherwise unexplained organ inflammation.
If ANA is positive in a compatible phenotype, select confirmatory antibodies by the suspected disease and local laboratory algorithm. Anti-dsDNA and complement can support lupus assessment; anti-Ro/La, Sm, RNP, centromere, topoisomerase and other antibodies have context-specific associations. Antibody nomenclature, assay performance and reporting differ, so read the laboratory comment and seek rheumatology or immunology advice for discordant results.
Tests do not replace safety assessment. A patient with haematuria, proteinuria, falling blood count, hypoxia or neurological change needs urgent organ evaluation even if ANA is pending or negative. Conversely, an asymptomatic low-titre ANA usually does not justify repeated panels, imaging or immunosuppression. Record why the test was ordered, what a positive or negative result changes and who will review it.
Key points
- RF is usually an IgM autoantibody directed against the Fc portion of IgG; it occurs in rheumatoid arthritis but also with age, chronic infection, smoking, other autoimmune disease and in some healthy people.
- Anti-CCP antibodies are more specific for rheumatoid arthritis and carry prognostic information, but a negative result does not exclude seronegative disease.
- Offer RF when clinical examination confirms synovitis and consider anti-CCP if RF is negative; never delay rheumatology referral while waiting for either result.
- ANA is a sensitive entry test for several connective-tissue diseases but has limited positive predictive value when ordered for fatigue or widespread pain without systemic features.
- Interpret ANA titre and laboratory pattern with symptoms, examination, FBC, renal function, urinalysis, complement and disease-specific antibodies.
- A positive ANA does not equal lupus, and a negative ANA makes some ANA-associated diseases less likely without excluding every connective-tissue or inflammatory condition.
- Repeating a positive antibody simply to monitor disease activity is usually unhelpful; follow clinical and organ-specific measures instead.
- Explain incidental results in plain language and document the remaining diagnostic uncertainty to prevent an unsupported autoimmune label following the patient indefinitely.
02Indications, selection and cautionsWhen it is useful, when urgency changes and important limitations.
RF and anti-CCP positivity in a patient with persistent small-joint synovitis strengthens rheumatoid arthritis probability and may identify higher risk of erosive progression.
Objective persistent swelling with negative RF and anti-CCP remains clinically important and requires referral rather than repeated antibody testing or diagnostic closure.
Inflammatory arthritis plus rash, Raynaud phenomenon, ulcers, sicca, serositis, cytopenia or renal findings creates sufficient context for ANA and targeted follow-on testing.
A low-prevalence presentation such as isolated fatigue or mechanical pain with no objective systemic features makes a positive ANA more likely to be incidental.
Proteinuria, active urine sediment, haemoptysis, hypoxia, myocarditis, severe cytopenia or neurological dysfunction requires urgent organ assessment regardless of antibody status.
03Method and interpretationA systematic approach to the test and its findings.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Rheumatoid factorFirst step - Why
- Support diagnosis and prognosis when rheumatoid arthritis is suspected from persistent synovitis.
- Interpretation and limitations
- Interpret concentration, assay range and phenotype. RF can be positive in chronic infection and other diseases, and negative rheumatoid arthritis is common enough that clinical referral remains essential.
- 02
Anti-CCP antibody - Why
- Provide more specific serological support and prognostic information in suspected rheumatoid arthritis.
- Interpretation and limitations
- A positive result meaningfully raises probability in the right phenotype; a negative result does not exclude disease and should not delay early treatment assessment.
- 03
Antinuclear antibody - Why
- Screen for ANA-associated connective-tissue disease when symptoms and organ findings establish reasonable pre-test probability.
- Interpretation and limitations
- Review titre, pattern, assay and laboratory comment. Positivity alone is not a diagnosis and should trigger only phenotype-directed, not blanket, follow-on testing.
- 04
Disease-specific nuclear antibodies and complement - Why
- Refine a suspected lupus, Sjögren, systemic-sclerosis or overlap phenotype and assess selected activity or risk.
- Interpretation and limitations
- Order according to clinical and laboratory algorithms. Anti-dsDNA and complement trends may inform lupus care but must be reconciled with urine, renal function and symptoms.
- 05
FBC, renal profile and urinalysis - Why
- Detect cytopenia and renal organ involvement that determine urgency more directly than serology.
- Interpretation and limitations
- Protein, blood, casts, falling cell counts or renal function change can signal active systemic disease and warrant urgent specialist assessment even before antibodies return.
04Clinical next stepsHow the result changes management or prompts escalation.
01Persistent synovitisRefer first and use serology as supportFirst stepExamination confirms persistent joint swelling compatible with rheumatoid arthritis.+
- 1Request RF and consider anti-CCP with baseline FBC, renal and liver tests, while documenting joint distribution, duration and function.
- 2Send rheumatology referral immediately rather than waiting for the results, because negative serology and normal markers do not exclude disease.
- 3Interpret positive antibodies as probability and prognostic evidence within the specialist assessment, not as permission for unsupervised long-term immunosuppression.
02Systemic phenotypeLink ANA to organ assessmentClinical features suggest lupus, Sjögren syndrome, systemic sclerosis or an overlap connective-tissue disorder.+
- 1Perform full systemic review and examination, FBC, renal profile and urinalysis, then request ANA and phenotype-directed follow-on tests through the local algorithm.
- 2EscalationEscalate organ-threatening findings immediately and involve rheumatology, renal, respiratory or another specialty without waiting for a complete antibody profile.
- 3Use antibody specificity, complement, organ results and longitudinal features to refine diagnosis and counselling after urgent threats are addressed.
03Unexpected positive resultReconstruct pre-test probabilityRF or ANA is positive after testing a nonspecific or low-probability presentation.+
- 1Verify the original indication, titre or concentration, assay pattern and any objective inflammatory or organ feature that was present before testing.
- 2Assess plausible non-rheumatic explanations such as infection, age or medicine exposure, and avoid repeating broad panels merely to seek confirmation.
- 3Explain that antibodies are risk markers rather than diagnoses, provide safety-netting for specific new features and discharge from testing when no clinical syndrome emerges.
05Risks, monitoring and follow-upComplications, safety checks and further assessment.
- Track clinical synovitis and function rather than serial RF or anti-CCP concentrations.
- In systemic disease, monitor the threatened organ with urine, renal, blood-count, respiratory or cardiac measures appropriate to the phenotype.
- Review every pending antibody result with the original pre-test question visible.
- Document counselling when a result is likely incidental to prevent inappropriate disease labelling.
- Reassess infection before attributing new inflammation or a raised RF to autoimmune activity.
06Special situationsVariants, exceptions and circumstances that change the usual approach.
Specificity depends on setting
Even a technically specific antibody creates more false-positive interpretations when used indiscriminately in people with very low pre-test probability.
Anti-CCP is not a gatekeeper
Its absence lowers probability but cannot override objectively persistent synovitis or justify delay in referral.
ANA is an entry point
The result begins a phenotype-directed interpretation; it is not a final label and should not trigger every available extractable antibody.
Organs outrank antibodies
Urine, blood count, oxygenation and neurological findings determine urgency while serology remains pending or equivocal.
Assays are not interchangeable
Method, reference range and reporting pattern differ across laboratories, so compare longitudinal results cautiously and read technical comments.
07Common pitfallsFrequent interpretation and management errors.
- 01
Delaying referral for persistent synovitis until anti-CCP becomes positive.
- 02
Diagnosing lupus from ANA positivity in isolated fatigue or widespread pain.
- 03
Repeating RF or ANA as a routine disease activity marker.
- 04
Ordering an extended antibody panel without a clinical phenotype.
- 05
Ignoring urine or organ abnormalities because screening serology is negative.